CAPTRUST Financial Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-15,829
Closed -$157K 4907
2021
Q3
$157K Hold
15,829
﹤0.01% 1734
2021
Q2
$157K Sell
15,829
-767
-5% -$7.72K ﹤0.01% 1690
2021
Q1
$165K Sell
16,596
-2,752
-14% -$29.3K ﹤0.01% 1612
2020
Q4
$209K Buy
+19,348
New +$199K ﹤0.01% 1165

Other funds holding STLN

CAPTRUST Financial Advisors's STLN Position: Q4 2021 in Review

CAPTRUST Financial Advisors sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 15,829 shares — an estimated $157K sold.

CAPTRUST Financial Advisors first reported a position in STLN in Q4 2020 and held it in 4 quarters. The position peaked at $209K in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • CAPTRUST Financial Advisors reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 15,829 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $157K.
  • CAPTRUST Financial Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $209K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.